Euromedica Kyanous Stavros — Clinical Trial Site

14 Registered trials

4 Currently recruiting

Organisation

Euromedica Kyanous Stavros

Location

Thessaloniki, Greece

Identifier

ORG-100048912

Address

Vizyis Vyzantos 1, 546 36, Greece

Departments

Department of Rheumatology
Rheumatology
Rheumatology Department

Clinical trials at this site (14)

Search interface

Phase 3 Study of Telitacicept in Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) Not authorised

2024-512716-21-00 Moderately to Severely Active Systemic Lupus Erythemato 5
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Systemic Sclerosis 4 2025-06-27
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Sjögren’s Syndrome 5 2025-05-16
Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting

2024-514354-67-00 Systemic lupus erythematosus 5 2024-11-01
A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended

2024-516745-39-00 Cutaneous lupus erythematosus 4 2025-07-11
A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Systemic Lupus Erythematosus 4 2024-10-22
A research study to evaluate the effects of a new oral medicine called cenerimod in adults with systemic lupus erythematosus Ended

2024-515870-28-00 Moderate to severe systemic lupus erythematosus 5 2024-10-22
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended

2023-508654-26-00 Systemic lupus erythematosus 4 2022-03-15
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended

2023-507680-19-00 Sjögren’s Syndrome 4 2024-11-28
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509783-23-00 Diffuse Cutaneous Systemic Sclerosis 4 2023-02-24
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509782-20-00 Diffuse Cutaneous Systemic Sclerosis 4 2021-11-11